全文获取类型
收费全文 | 617篇 |
免费 | 52篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 4篇 |
妇产科学 | 9篇 |
基础医学 | 74篇 |
口腔科学 | 2篇 |
临床医学 | 30篇 |
内科学 | 166篇 |
皮肤病学 | 1篇 |
神经病学 | 33篇 |
特种医学 | 2篇 |
外科学 | 24篇 |
综合类 | 13篇 |
预防医学 | 92篇 |
眼科学 | 58篇 |
药学 | 36篇 |
肿瘤学 | 129篇 |
出版年
2023年 | 4篇 |
2022年 | 11篇 |
2021年 | 14篇 |
2019年 | 5篇 |
2018年 | 10篇 |
2017年 | 10篇 |
2016年 | 5篇 |
2015年 | 15篇 |
2014年 | 22篇 |
2013年 | 27篇 |
2012年 | 42篇 |
2011年 | 32篇 |
2010年 | 14篇 |
2009年 | 15篇 |
2008年 | 30篇 |
2007年 | 27篇 |
2006年 | 32篇 |
2005年 | 40篇 |
2004年 | 32篇 |
2003年 | 27篇 |
2002年 | 22篇 |
2001年 | 9篇 |
2000年 | 25篇 |
1999年 | 15篇 |
1998年 | 10篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 8篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 15篇 |
1989年 | 5篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 11篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1981年 | 4篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 4篇 |
1974年 | 6篇 |
1973年 | 6篇 |
1972年 | 7篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1969年 | 3篇 |
排序方式: 共有674条查询结果,搜索用时 8 毫秒
1.
2.
Low-dose aspirin for migraine prophylaxis 总被引:3,自引:0,他引:3
The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial that studied low-dose aspirin (325 mg every other day) therapy among 22,071 US male physicians aged 40 to 84 years. Annual follow-up questionnaires requested information on the occurrence of numerous medical conditions including migraine. At the end of 60 months, morbidity follow-up was 99.7% complete, and the reported consumption of aspirin or other platelet-active drugs was 86% in the aspirin group and 14% in the placebo group. Of those randomized to aspirin, 661 (6.0%) reported migraine at some time after randomization, as compared with 818 (7.4%) of those allocated to the placebo group, representing a statistically significant 20% reduction in recurrence rate. The rate of self-report of ordinary headache was similar in the two groups. These data indicate that migraine is mediated, at least in part, by the effects of platelets and suggest that low-dose aspirin should be considered for prophylaxis among those with a history of established migraine. 相似文献
3.
O. B. Eden J. S. Lilleyman S. Richards M. P. Shaw J. Peto 《British journal of haematology》1991,78(2):187-196
During the 1970s, despite apparently similar treatment, the prognosis for children with lymphoblastic leukaemia (ALL) improved more in some countries, notably the United States and West Germany, than in others. To find out why, the first phase of the United Kingdom (UK) Medical Research Council (MRC) childhood ALL trial, UKALL VIII, was designed to see whether similar results to the United States Children's Cancer Study Group (CCSG) could be obtained in the U.K. using an identical protocol (CCG 162). Protocol 162 was one of a series of regimens devised by the American Children's Cancer Study Group in the 1970s and was used specifically for their average risk patients (all children with ALL with an initial white cell count up to 50 x 10(9)/l except those aged 3-6 years with white cell counts under 10 x 10(9)/l). One arm (1A) of their study was adopted by the MRC for all children in the U.K. aged 0-14 years with confirmed ALL. Eight hundred and twenty-nine consecutive patients were entered between 1980 and 1984. The first 199 patients formed a single arm study as per the original protocol 162 (arm 1A), but the subsequent 630 children were randomized to receive or not two doses of daunorubicin on the first 2 d of induction. This randomization was an attempt to answer the important question as to whether event-free survival was influenced by the use of four rather than three induction agents. A second randomization between 2 and 3 years continuing therapy was also introduced at this stage as it had been by the CCSG in their protocol. With a minimum follow up period of more than 5 years, disease-free survival for the whole group is 55%, a considerable improvement on all previous UKALL trials. Results for patients directly comparable with those in CCSG 162 ('average risk' patients) and their American counterparts were similar. Daunorubicin was associated with more early deaths but improved disease-free survival for those achieving remission. More children relapsed who stopped treatment after 2 years than those who continued for 3, but this was balanced by increased treatment mortality in the third year. The fact that for UKALL VIII the results were similar to those of the CCSG suggests that previous MRC protocols were not sufficiently sustained and intensive, particularly during the maintenance phase of treatment.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
4.
5.
Chen ZM Sandercock P Pan HC Counsell C Collins R Liu LS Xie JX Warlow C Peto R 《Stroke; a journal of cerebral circulation》2000,31(6):1240-1249
BACKGROUND AND PURPOSE: Long-term daily aspirin is of benefit in the years after ischemic stroke, and 2 large randomized trials (the Chinese Acute Stroke Trial [CAST] and the International Stroke Trial [IST]), with 20 000 patients in each, have shown that starting daily aspirin promptly in patients with suspected acute ischemic stroke also reduces the immediate risk of further stroke or death in hospital and the overall risk of death or dependency. However, some uncertainty remains about the effects of early aspirin in particular categories of patient with acute stroke. METHODS: To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups. This represents 99% of the worldwide evidence from randomized trials. RESULTS: There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2. 3%] control, 2P<0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5. 4%, 2P=0.05). Against these benefits, there was an increase of 2 (SD 1) per 1000 in hemorrhagic stroke or hemorrhagic transformation of the original infarct (1.0% versus 0.8%, 2P=0.07) and no apparent effect on further stroke of unknown cause (0.9% versus 0.9%). In total, therefore, there was a net decrease of 9 (SD 3) per 1000 in the overall risk of further stroke or death in hospital (8.2% versus 9.1%, 2P=0.001). For the reduction of one third in recurrent ischemic stroke, subgroup-specific analyses found no significant heterogeneity of the proportional benefit of aspirin (chi(2)(18)=20. 9, NS), even though the overall treatment effect (chi(2)(1)=24.8, 2P<0.000001) was sufficiently large for such subgroup analyses to be statistically informative. The absolute risk among control patients was similar in all 28 subgroups, so the absolute reduction of approximately 7 per 1000 in recurrent ischemic stroke does not differ substantially with respect to age, sex, level of consciousness, atrial fibrillation, CT findings, blood pressure, stroke subtype, or concomitant heparin use. There was no good evidence that the apparent decrease of approximately 4 per 1000 in death without further stroke was reversed in any subgroup or that in any subgroup the increase in hemorrhagic stroke was much larger than the overall average of approximately 2 per 1000. Finally, there was no significant heterogeneity between the reductions in the composite outcome of any further stroke or death (chi(2)(18)=16.5, NS). Among the 9000 patients (22%) randomized without a prior CT scan, aspirin appeared to be of net benefit with no unusual excess of hemorrhagic stroke; moreover, even among the 800 (2%) who had inadvertently been randomized after a hemorrhagic stroke, there was no evidence of net hazard (further stroke or death, 63 aspirin versus 67 control). CONCLUSIONS: Early aspirin is of benefit for a wide range of patients, and its prompt use should be routinely considered for all patients with suspected acute ischemic stroke, mainly to reduce the risk of early recurrence. 相似文献
6.
7.
Jenkinson C Fitzpatrick R Swash M Peto V;ALS-HPS Steering Group 《Journal of neurology》2000,247(11):835-840
The measurement of functioning and well-being from the perspective of the patient has in recent years become central to the
assessment of health and the evaluation of treatment regimes. The past decade has seen an enormous growth in the application
of measures designed to assess quality of life in a vast array of medical specialities. However, the use of such measures
in neurology has been relatively limited, and this has certainly been the case in amyotrophic lateral sclerosis (ALS). The
European ALS Health Profile Study is a longitudinal survey of patients diagnosed with ALS or other motor neurone diseases
in which patients are aksed to complete questionnaires concerning their subjective health status. Data from clinical assessments
are also collected. It is intended that the information collected will provide more systematic and detailed evidence of the
impact of the disease from the perspective of the patient. This contribution documents results from baseline assessment obtained
from data supplied by clinicians, carers and patients themselves. Three outcome measured are assessed in this paper: the SF-36,
a generic measure of well being and functioning, the ALS Functinal Rating Scale and the Carer Strain Index. The evidence presented
here suggests that these measures provide a meaningful and valid picture of the impact of the disease. The data indicate that
ALS has substantial adverse effects both upon the functioning and well being of patients and carers, as well as an association
between the emotional health status of patients and carers, and between the physical health status of patients and carers.
Received: 4 January 2000 / Received in revised form: 15 March 2000 / Accepted: 3 May 2000 相似文献
8.
9.
Olivia Fletcher Lorna Gibson Nichola Johnson Dan R Altmann Jeffrey M P Holly Alan Ashworth Julian Peto Isabel Dos Santos Silva 《Cancer epidemiology, biomarkers & prevention》2005,14(1):2-19
We reviewed all English-language articles on associations among circulating levels of the insulin-like growth factors (IGF) and their binding proteins (IGFBP), polymorphisms in their genes, and breast cancer risk. In premenopausal women, five of eight IGF-I studies and four of six IGFBP-3 studies of circulating levels found that women in the highest quantile had more than twice the risk of developing breast cancer of those in the lowest, although in some this effect was only apparent at young ages. In postmenopausal women, however, there was no consistent effect. A simple sequence length polymorphism 1 kb 5' to IGF-I was examined in relation to circulating levels of IGF-I (12 studies) or breast cancer risk (4 studies), but there was no convincing evidence of any effect. For an A/C polymorphism 5' to IGFBP-3, all three studies were consistent with a modest effect on circulating levels, but no evidence of a direct effect on breast cancer risk was seen in the only relevant study. Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely. 相似文献
10.